Abstract
Chemotherapy is a standard treatment method for the patients with locally advanced breast cancer. Lately, cyclophosphamide (CYP) and doxorubicin (DOX) are used as the major chemotherapeutic agents especially for the treatment of breast cancer. Till date, no serum biomarker has been able to provide an early diagnosis of breast cancer. This study aimed to assess inflammatory, cardiac, renal and hematological markers in 56 breast cancer patients (BCP) before, during and after termination of chemotherapy with CYP and DOX. Blood samples were collected from the patients at the each treatment stages mentioned above. These samples were assessed for interleukin 6 (IL-6), interleukin 10 (IL-10), lactate dehydrogenase (LDH), creatine kinase (CK), creatinine, hemoglobin (Hb), leukocyte, platelet and Na+/K+-ATPase levels either by ELISA or colorimetric methods. The results suggest a significant increase in IL-6 level at all the stages in BCP as compared to control group. On the other hand, IL-10, CK and Na+/K+-ATPase levels were found to be significantly declined during all the stages. Moreover, the majority of hematological parameters remained unchanged throughout the treatment period with the exception of creatinine and Hb which showed slight modulation in their level at different stages. Based on the results, we conclude that breast cancer and co-treatment with CYP and DOX, interfere arious biological markers, thereby, showing the physiological imbalance.
| Original language | English |
|---|---|
| Pages (from-to) | 2923-2928 |
| Number of pages | 6 |
| Journal | Journal of Cellular Biochemistry |
| Volume | 119 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2018 |
Bibliographical note
Publisher Copyright:© 2017 Wiley Periodicals, Inc.
Funding
The authors are grateful to the researchers of the Laboratory of Research in Experimental Neurochemistry (LAPNEX/ UFPI), Laboratory of Research in Toxicology Genetic (LAPGENIC/UFPI), Fundação de Amparo a Pesquisa do Estado do Piauí FAPEPI and Coordenação de Aperfeiçoa-mento de Pessoal de Nível Superior (CAPES) for materials, equipments, scholarship, and collaborations. ST, NRJ, and MZA are grateful to the research facility provided by King Fahd Medical Research Center (KFMRC), King Abdulaziz University, Jeddah, Saudi Arabia. We dedicate this work to our colleague “Rivelilson Mendes de Freitas” who left this world for heavenly abode. The authors are grateful to the researchers of the Laboratory of Research in Experimental Neurochemistry (LAPNEX/UFPI), Laboratory of Research in Toxicology Genetic (LAPGENIC/UFPI), Fundação de Amparo a Pesquisa do Estado do Piauí FAPEPI and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) for materials, equipments, scholarship, and collaborations. ST, NRJ, and MZA are grateful to the research facility provided by King Fahd Medical Research Center (KFMRC), King Abdulaziz University, Jeddah, Saudi Arabia. We dedicate this work to our colleague “Rivelilson Mendes de Freitas” who left this world for heavenly abode.
| Funders |
|---|
| Coordenação de Aperfeiçoamento de Pessoal de Nível Superior |
| King Abdulaziz University |
| Fundação de Amparo à Pesquisa do Estado do Piauí |
| Universidade Federal do Piauí |
| King Fahd Medical City |
Keywords
- breast cancer
- chemotherapy
- cyclophosphamide
- cytokines
- doxorubicin
ASJC Scopus subject areas
- Biochemistry
- Molecular Biology
- Cell Biology
